



For immediate distribution
Source: DIAGNOS inc.

2012.10.17

CARA licensing agreement of \$700,000 with Intelligent Retina Imaging Systems Inc. for a 3 year period.

Brossard, Quebec, Canada – October 17, 2012 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today the signing of a non exclusive licensing agreement with Intelligent Retina Imaging Systems (IRIS) for the use of CARA (Computer Assisted Retinal Analysis) to its customer base in the Pensacola Florida region including Alabama and Georgia USA.

Intelligent Retina Imaging Systems (IRIS) will pay DIAGNOS \$700,000 over a three year period. “We believe that our IRIS model, using CARA, is an excellent solution in helping to prevent vision loss in the diabetic population. We have the ability to preserve the vision of most, if not all, diabetic patients if we can treat them at the appropriate time.” said Dr Sunil Gupta, President of IRIS.

Intelligent Retina Imaging Systems (IRIS) is excited to move forward with this agreement. Currently almost 70% of our patients are not being seen for their annual exam as recommended, and we are confident that CARA will have a positive effect in changing this.” said Dr Alan Franklin, MD, PhD, a partner in IRIS.

“We are pleased to be working in collaboration with Intelligent Retina Imaging Systems. Our partnership with IRIS is a giant step forward in the commercialization of CARA. We will now have access to local retina specialists that will provide services and optimal patient care throughout the Americas and the world. Understanding local culture and needs is essential to sustain long term success in the USA and around the world. This 3 year agreement is the beginning of long sales process initiated last year in the USA. (Reference press release dated November 2011). Diagnos’ team is very enthusiastic about taking a more effective role in the healthcare solution market for the USA.” said André Larente, DIAGNOS’ President.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time and has been issued a licence by Health Canada and FDA for commercialization.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources and healthcare.



For immediate distribution
Source: DIAGNOS inc.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President
DIAGNOS Inc.
T.: (450) 678-8882
alarente@diagnos.com

Louis Morin
Bid Capital Markets
T.: (514) 845-1101
bidcapital@videotron.ca